CXM Key Stats
- CARDIUM THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report May 15
- Cardium Presents First Quarter 2013 Financial Results And Reports On Recent Deve... May 15
- CARDIUM THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statement... May 6
- Cardium Announces Generx Publication In Molecular Therapy PR Newswire May 2
- Cardium Announces Excellagen Presentation at the Symposium on Advanced Wound Car... Apr 30
- CARDIUM THERAPEUTICS, INC. Financials Apr 11
- CARDIUM THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statement... Apr 11
- Cardium Presents Year-End 2012 Financial Results And Recent Developments PR Newswire Apr 5
- Cardium Announces $4.0 Million Preferred Stock Financing And Reports On Exchange... Apr 5
- CARDIUM THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive ... Apr 5
CXM Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Cardium Therapeutics is down 60.86% over the last year vs S&P 500 Total Return up 31.45%, Immunomedics down 10.59%, and Sangamo BioSciences up 75.63%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for CXM
Pro Report PDF for CXM
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download CXM Pro Report PDF
Pro Strategies Featuring CXM
Did Cardium Therapeutics make it into our Pro Portfolio Strategies?